Combination therapy in multiple sclerosis

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 95-103

  Fernández, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Combination; Immunomodulators; Immunosupressants; Multiple sclerosis; Neuroprotective; Treatment

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; ESTRIOL; FINGOLIMOD; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUROPROTECTIVE AGENT; NEUROTROPHIN; SB 683699; STEROID; TERIFLUNOMIDE; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALGORITHM; ARTICLE; AXONAL INJURY; CELL DAMAGE; CELLULAR IMMUNITY; CLINICAL DECISION MAKING; CONSENSUS; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNOMODULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATIENT INFORMATION; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 34447104601     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.08.019     Document Type: Article

References (71)

1. Wingerchuk D.M., Lucchinetti C.F., and Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab Invest 81 (2001) 263-281
2. Hemmer B., Cepok S., Nessler S., and Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 15 (2002) 227-231
3. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 (2002) 291-301
4. Liblau R.S., and Fontaine B. Recent advances in immunology in multiple sclerosis. Curr Opin Neurol 11 (1998) 293-298
5. Gran B., Hemmer B., Vergelli M., McFarland H.F., and Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 45 (1999) 559-567
6. Albert L.J., and Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 341 (1999) 2068-2074
7. Johnson H.M., Torres B.A., and Soos J.M. Superantigens: structure and relevance to human disease. Proc Soc Exp Biol Med 212 (1996) 99-109
8. Brocke S., Piercy C., and Steinman L. Superantigens in demyelinating disease. Springer Semin Immunopathol 18 (1996) 51-56
9. Vanderlugt C.L., Begolka W.S., Neville K.L., Katz-Levy Y., Howard L.M., Eagar T.N., et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 164 (1998) 63-72
10. Goebels N., Hofstetter H., Schmidt S., Brunner C., Wekerle H., and Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 Pt 3 (2000) 508-518
11. Vanderlugt C.J., and Miller S.D. Epitope spreading. Curr Opin Immunol 8 (1996) 831-836
12. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Johnson J.M., Mathisen P.M., et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 164 (1998) 93-100
13. Kumar V. Determinant spreading during experimental autoimmune encephalomyelitis: is it potentiating, protecting or participating in the disease?. Immunol Rev 164 (1998) 73-80
14. Voskuhl R.R. Myelin protein expression in lymphoid tissues: implications for peripheral tolerance. Immunol Rev 164 (1998) 81-92
15. Giovannoni G., and Hartung H.P. The immunopathogenesis of multiple sclerosis and Guillain-Barre syndrome. Curr Opin Neurol 9 (1996) 165-177
16. Coyle P.K. The neuroimmunology of multiple sclerosis. Adv Neuroimmunol 6 (1996) 143-154
17. Martino G., and Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 12 (1999) 309-321
18. Navikas V., and Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45 (1996) 322-333
19. Lassmann H., Bruck W., Lucchinetti C., and Rodriguez M. Remyelination in multiple sclerosis. Mult Scler 3 (1997) 133-136
20. Lucchinetti C.F., Bruck W., Rodriguez M., and Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6 (1996) 259-274
21. Storch M., and Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10 (1997) 186-192
22. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002) 911-920
23. Walsh M.J., and Tourtellotte W.W. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 163 (1986) 41-53
24. Sharief M.K., and Thompson E.J. Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 114 (1991) 184-195
25. Qin Y., Duquette P., Zhang Y., Talbot P., Poole R., and Antel J. Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102 (1998) 1045-1050
26. Owens G.P., Kraus H., Burgoon M.P., Smith-Jensen T., Devlin M.E., and Gilden D.H. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 43 (1998) 236-243
27. Baranzini S.E., Jeong M.C., Butunoi C., Murray R.S., Bernard C.C., and Oksenberg J.R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163 (1999) 5133-5144
28. Wingerchuk D.M., Lucchinetti C.F., and Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab Invest 81 (2001) 263-281
29. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., and Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 43 (1998) 465-471
30. Archelos J.J., Storch M.K., and Hartung H.P. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47 (2000) 694-706
31. Kieseier B.C., Storch M.K., Archelos J.J., Martino G., and Hartung H.P. Effector pathways in immune mediated central nervous system demyelination. Curr Opin Neurol 12 (1999) 323-336
32. Brosnan C.F., and Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 6 (1996) 243-257
33. Hartung H.P., and Rieckmann P. Pathogenesis of immune-mediated demyelination in the CNS. J Neural Transm Suppl 50 (1997) 173-181
34. Lassmann H. Basic mechanisms of brain inflammation. J Neural Transm Suppl 50 (1997) 183-190
35. Rodriguez M., and Lucchinetti C.F. Is apoptotic death of the oligodendrocyte a critical event in the pathogenesis of multiple sclerosis?. Neurology 53 (1999) 1615-1616
36. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 343 (1994) 271-275
37. Hartung H.P. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 8 (1995) 191-199
38. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 (2002) 75-85
39. Saoudi A., Simmonds S., Huitinga I., and Mason D. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J Exp Med 182 (1995) 335-344
40. Rodriguez M., and Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27 (1990) 12-17
41. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50 (2001) 169-180
42. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50 (1998) 398-402
43. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157 (2000) 267-276
44. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
45. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
46. Wekerle H. Immune pathogenesis of multiple sclerosis. Brain autoimmune reactivity and its control by neuronal function. Mult Scler 4 (1998) 136-137
47. Neumann H., and Wekerle H. Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J Neuropathol Exp Neurol 57 (1998) 1-9
48. Gonsette R. Tratamiento precoz de la progresión en la Esclerosis Múltiple. Cuadernos de Esclerosis Múltiple vol. 8 (2001) 6-21
49. Neuhaus O., Archelos J.J., and Hartung H.P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24 (2003) 131-138
50. Dhib-Jalbut S., Chen M., Henschel K., Ford D., Costello K., and Panitch. Links Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 8 (2002) 485-491
51. Hussien Y., Sanna A., Soderstrom M., Link H., and Huang Y.M. Links Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFNB and glatiramer acetate compared to monotherapy with IFN-beta. Mult Scler 1 (Feb 2004) 16-25
52. Lublin F., Cutter G., Elfont R., Khan R., Lisak H., McFarland H., et al. A trial to assess the safety of combining therapy with interferon beta1-a and glatiramer acetate in patients with relapsing MS. Neurology 56 (2001) A148
53. Lublin F., Baier M., Cutter G., Bever C., Elfont R., Khan O., et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-a and galtiramer acetate. Neurology 58 (2002) A85
54. Fernandez O., Guerrero M., Mayorga C., Munoz L., León A., Luque G., et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 249 (2002) 1058-1062
55. Markovic-Plese S., Bielekova B., Kadom N., Leist T.P., Martin R., Frank J.A., et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 60 (2003) 1849-1851
56. Lus G., Romano F., Scuotto A., Accardo C., and Cotrufo R. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 51 (2004) 15-20 [Electronic publication 2003 Nov 18]
57. Pulicken M., Bash C.N., Costello K., Said A., Cuffari C., Wilterdink J.L., et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 11 (2005) 169-174
58. Fernandez O., Fernandez V., and De Ramon E. Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci 223 (2004) 29-34
59. Patti F., Cataldi M.L., Nicoletti F., Reggio E., Nicoletti A., and Reggio A. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71 (2001) 404-407
60. Patti F., Amato M.P., Filippi M., Gallo P., Trojano M., and Comi G.C. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 223 (2004) 69-71
61. Reggio E., Nicoletti A., Fiorilla T., Politi G., Reggio A., and Patti F. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-twenty-four months follow-up. J Neurol 252 (2005) 1255-1261 [Electronic publication 2005 Jun 6]
62. Smith D.R., Weinstock-Guttman B., Cohen J.A., Wei X., Gutmann C., Bakshi R., et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11 (2005) 573-582
63. Calabresi P.A., Wilterdink J.L., Rogg J.M., Mills P., Webb A., and Whartenby K.A. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58 (2002) 314-317
64. Rowe V., Dressman L.A., Wang D., Hunter J.A., Feaster H.T., Rowe E.S., et al. High dose intravenous methotrexate in MS patients worsening despite avonex therapy: final results. Neurology 62 Suppl 5 (2004) A260-A261
65. Vermersch P., Waucquier N., Bourteel H., Stojkovic T., Ferriby D., Michelin E., et al. Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept) results of a phase II clinical trial. Neurology 62 7 Suppl 5 (2004)
66. Jeffery D.R., Chepuri N., Durden D., and Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Neurology 63 (2004) S41-S46
67. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 (2006) 911-923
68. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
69. Chaudhuri A. Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ 332 (2006) 416-419
70. Pozzilli C., Antonini G., Bagnato F., Mainero C., Tomassini V., Onesti E., et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249 (2002) 50-56
71. Kanwar J.R., Kanwar R.K., and Krissansen G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127 (2004) 1313-1331 [Electronic publication 2004 May]